Indonesia
South-East Asia Region
OTHERS
Confirmed cases
per
1000 population/
OTHERS
Parasite prevalence
PR
(PP)
Insufficient data
0
Insufficient data
No cases
00.1
Very low PP
00.1
Very low PP
0.11.0
020
0.11.0
020
PP
>75
4060
6080
No cases
1.010
PP
2040
Based on 2012 reported data
2040
>75
4060
6080
80100
Based on 2012 reported data
80100
I. Epidemiological profile
High transmission (> 1 case per 1000 population)
Low transmission (01 cases per 1000 population)
Malaria-free (0 cases)
Total
Insufficient data
Insufficient data
0
PF-RATIO
1.010
Population
Proportion of cases
PF-RATIO
due
to P. falciparum
PR
2013
Parasites and vectors
42500000
109900000
97400000
249800000
17
44
39
Major plasmodium species: P. falciparum (56%), P. vivax (44%)
Major anopheles species:
An. sundaicus, An. balabacensis, An. maculatus, An. farauti, An. subpictus, An. subpictus
Programme phase:
Reported confirmed cases:
Reported deaths:
Control
343527
45
II. Intervention policies and strategies
Intervention Policies/strategies
Yes/ Year
No adopted
Intervention Policies/strategies
Yes/ Year
No adopted
ITN
ITNs/LLINs distributed free of charge
ITNs/LLINs distributed to all age groups
Yes
Yes
2006
2004
IRS
IRS is recommended
DDT is authorized for IRS
Yes
No
1959
Larval control Use of larval control recommended
Yes
1990
Surveillance ACD for case investigation (reactive)
ACD of febrile cases at community level (pro-active)
Mass screening is undertaken
Uncomplicated P. falciparum cases routinely admitted
Uncomplicated P. vivax cases routinely admitted
Yes
Yes
Yes
Yes
Yes
IPT
IPT used to prevent malaria during pregnancy
N/A
Diagnosis
Patients of all ages should receive diagnostic test
Malaria diagnosis is free of charge in the public sector
Yes
Yes
2007
1959
Treatment
ACT is free for all ages in public sector
Yes 2004
Artemisinin-based monotherapies withdrawn
Single dose of primaquine is used as gametocidal medicine for P. falciparum Yes
Primaquine is used for radical treatment of P. vivax
Yes
G6PD test is a requirement before treatment with primaquine
No
Directly observed treatment with primaquine is undertaken
No
System for monitoring of adverse reactions to antimalarials exists
Yes
Year
Antimalaria treatment policy
Medicine
adopted
First-line treatment of unconfirmed malaria
First-line treatment of P. falciparum
Treatment failure of P. falciparum
Treatment of severe malaria
Treatment of P. vivax
Dosage of primaquine for radical treatment of P. vivax
AS+AQ; DHA-PP+PQ
2008
QN+D+PQ 2004
AM; AS; QN
2004
AS+AQ; DHA-PP+PQ(14d)
2008
0.25 mg/kg (14 days)
Type of RDT used
P.f + P.v specific (Combo)
Therapeutic efficacy tests (clinical and parasitological failure, %)
Medicine
Year
Min
Median
Max
Follow-up No. of studies
Species
World Bank
ITN and IRS coverage
Others
WHO_UNICEF
USAID/PMI
Worldbank (USD)
Global Fund (USD)
Malaria budget (USD)
(%)
Survey source: DHS 2003,
DHS 2007, DHS 2012
Cases tested and treated in public sector
Cases (%)
Survey source: DHS 2007
Cases per 1000
Management and other costs
Survey source: DHS 2012
Human Resources & technical Assistance
Monitoring and evaluation
Antimalarial medicines
Diagnostics
2000 2001 2002 2003 2004 2005 ITNs2006 2007 2008 2009 2010 2011 2012 2013
Suspected cases tested
Antimalarials distributed vs reported cases
Insecticide & spraying materials
<5 with fever with finger/heel stick (survey)
ACTs distributed vs reported P. f. cases
Primaquine distributed vs reported P. v. cases
ACTs as % of all antimalarials received by <5 (survey)
At high risk protected with ITNs
All ages who slept under an ITN (survey)
Cases
Households
withtracked
at least one ITN
At high risk protected with IRS Points
At high risk protected with IRS
Test positivity
% fever cases <5 seeking treatment at public HF (survey)
2.0
1.6
1.2
0.8
0.4
0
100
80
60
40
20
0
All ages who slept under an ITN (survey)
At high risk protected with IRS
100
80
60
40
20
0
5
4
3
2
1
0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
V. Impact
Reporting completeness
Suspected cases tested
<5 with fever with finger/heel stick (survey)
ACTs as % of all antimalarials received by <5
Primaquine distributed vs reported P.v cases points
Primaquine distributed vs reported P.v cases
ACTs distributed vs reported P.f cases points
ACTs distributed vs reported P.f cases
Antimalarials
vs reported
points2010 2011 2012 2013
2000 2001 2002 2003 2004
2005 distributed
2006 2007
2008 cases
2009
distributedrate
vs reported cases RDT positivity rate
Parasite prevalence (survey) Antimalarials
Slide positivity
Estimated cases detected - top
ConfirmedEstimated
malaria
cases
per- 1000
cases
detected
bottomand ABER
Fever cases INF5 seeking treatment at public hf
Reporting completeness points
Reporting completeness
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
ABER (microscopy & RDT)
Cases (all species)
Funding source(s): Global Fund,
WHO, UNICEF
Others
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
At high risk protected with ITNs
Households with at least one ITN
100
80
60
40
20
0
WHO/UNICEF
Tests (%)
Population (%)
IV. Coverage
USAID/PMI
Cases (P. vivax)
Malaria admissions and deaths
2.0
1.6
1.2
0.8
0.4
0
Parasite prevalence
Slide positivity rate points
Slide positivity rate
RDT positivity rate points
RDT positivity rate
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Admissions (all species)
Deaths (all species)
1000
800
600
400
200
0
Deaths
Global Fund
Pie chart includes 100%
of total contributions
Insecticides & spray materials
ITNs
Diagnostic testing
Antimalarial medicines
Monitoring and evaluation
Human resources & technical assistance
Management and other costs
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Government
100
80
60
40
20
0
Financing by intervention in 2013
Sources of financing
Admissions
50
40
30
20
10
0
ABER (%)
Contribution (US$m)
III. Financing
Admissions (P. vivax)
Deaths (P. vivax)
Impact: Insufficiently consistent data to assess trends
Aber (microscopy
& RDT)
Cases
(p.vivax) points
Cases (p.vivax)
Deaths (P.vivax) points
Admissions (P.vivax) points
WORLD
MALARIA REPORT
2014 | 113
Deaths (P.vivax)
Admissions (P.vivax)
Cases (all species) points
Admissions (all species) points
Cases (all species)
Admissions (all species)
Deaths (all species) points
Deaths (all species)
